Drug Type Small molecule drug |
Synonyms AX 0085, AXO-1801 |
Target |
Action inhibitors, antagonists |
Mechanism AXL inhibitors(AXL receptor tyrosine kinase inhibitors), EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), IDO1 inhibitors(Indoleamine 2,3-dioxygenase inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Preclinical | South Korea | 01 Oct 2025 | |
Triple Negative Breast Cancer | Preclinical | South Korea | 26 May 2023 | |
Adenocarcinoma of Lung | Preclinical | South Korea | 22 Dec 2021 |